# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and lowers the pric...
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estima...
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement wit...
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives ...
Oppenheimer analyst Leland Gershell initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform rating an...
HC Wainwright & Co. analyst Oren Livnat maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price...